Evaluation of a multiplex panel of immune‐related markers in cervical secretions: A methodologic study
Although persistent carcinogenic human papillomavirus (HPV) infection is necessary for cervical carcinogenesis, the cofactors involved in HPV persistence and disease progression are poorly understood. Chronic cervical inflammation may increase risk, but few studies have measured immune markers (cyto...
Gespeichert in:
Veröffentlicht in: | International journal of cancer 2014-01, Vol.134 (2), p.411-425 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Although persistent carcinogenic human papillomavirus (HPV) infection is necessary for cervical carcinogenesis, the cofactors involved in HPV persistence and disease progression are poorly understood. Chronic cervical inflammation may increase risk, but few studies have measured immune markers (cytokines, chemokines and soluble receptors) in cervical secretions. We evaluated the performance of 74 multiplexed, bead‐based immune markers in cervical secretions from three groups of women with biopsy evaluation of cervical intraepithelial neoplasia (CIN), (i) 80% interclass correlation coefficients (ICCs) acceptable for epidemiologic studies. Within‐batch coefficients of variation (CVs) of ≥25% indicated room for assay improvement. Secondarily, we explored associations between marker levels and CIN/HPV status adjusted for matching variables, assay batch, age and number of sexual partners. Sixty‐two markers (84%) had >25% detectability and ICCs > 80%. Of those, 53 (85%) had CVs < 25%. Using these preliminary data, we found that HPV positivity was associated with increased eotaxin‐1 [odds ratio (OR): 15.63, 95% confidence interval (CI): 1.26–200.00] and G‐CSF (OR: 12.99, 95% CI: 1.10–142.86) among CIN‐negative women. There was suggestive evidence that higher chemoattractant marker levels were associated with CIN2/3 (e.g., MIP‐1delta, OR: 4.48, 95% CI: 0.87–23.04 versus |
---|---|
ISSN: | 0020-7136 1097-0215 |
DOI: | 10.1002/ijc.28354 |